ATHIRA PHARMA, INC. CLASS ACTION ALERT: Wolf Haldenstein

NEW YORK, June 28, 2021 (GLOBE NEWSWIRE) – Wolf Haldenstein Adler Freeman & Herz LLP announces that it has filed a class action lawsuit over federal securities in the United States District Court for the Western District of Washington on behalf of investors who bought Athira became common stock of Pharma, Inc. (“Athira” or the “Company”) (NASDAQ: ATHA) pursuant to and / or traceable to the registration statement and prospectus (collectively the “Registration Statement”) relating to the Company’s initial issue dated September 2020 issued a public offering (“IPO” or the “Offer”) at a price of $ 17.00.

All investors who bought Athira Pharma, Inc. and any losses incurred are urged to contact the company immediately [email protected] or (800) 575-0735 or (212) 545-4774. You can get more information about the promotion or join the case on our website, www.whafh.com.

If you have suffered losses in the shares of Athira Pharma, Inc., You can, no later than 08/24/2021, request that the court appoint you as the lead plaintiff of the proposed group. Please contact Wolf Haldenstein to learn more about your rights as an Athira Pharma, Inc. investor.

PLEASE CLICK HERE TO JOIN CASE

Athira is a late-stage clinical biopharmaceutical company focused on developing small molecules to restore neuronal health and stop neurodegeneration.

On June 17, 2021, after the market closed, Athira announced that she would be her President and Chief Executive Officer, Dr. Leen Kawas (“Kawas”) has been on leave pending review of the measures resulting from her doctoral thesis in Washington State University (“WSU”).

On the same day, STAT published an article stating that the WSU was investigating claims that Dr. Kawas “published several articles with altered images while she was a PhD student”. These publications “are fundamental to Athira’s efforts to treat Alzheimer’s disease” because they “represented that a certain”
Molecule affects the activity of HGF. ”Although Athira developed a different molecule than the one Kawas studied in the articles in question, her“ PhD thesis laid the biological foundations that Athira continues to use in her approach to treating Alzheimer’s disease ”.

As a result of this news, the company’s stock price fell $ 7.09, or approximately 39%, to close at $ 11.15 per share on June 18, 2021.

Wolf Haldenstein has extensive experience prosecuting securities class actions and derivatives disputes in state and federal courts and appeals courts across the country. The firm has lawyers in various fields of activity; and offices in New York, Chicago and San Diego. This firm’s reputation and expertise in shareholder and other class action lawsuits have been recognized repeatedly by the courts who have appointed them to key positions in complex securities, multi-district and consolidated litigation.

If you would like to discuss this measure or if you have any questions about your rights and interests in this case, please contact Wolf Haldenstein immediately by telephone at (800) 575-0735, by email at [email protected] or visit our website at www.whafh.com.

Contact:

Wolf Haldenstein Adler Freeman & Herz LLP
Patrick Donovan, Esq.
Gregory Stone, director of case and financial analysis
Email: [email protected], [email protected] or [email protected]
Tel: (800) 575-0735 or (212) 545-4774

This press release may be viewed as a solicitation in some jurisdictions subject to applicable laws and ethical rules.

Comments are closed.